Trial Profile
A real world study of Bortezomib in Combination with Melphalan and Prednisone in Stem Cell Transplant (Sct) Ineligible Multiple Myeloma (Mm) Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Dec 2018
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Melphalan; Prednisone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 01 Dec 2018 New trial record
- 14 Nov 2018 Results assessing Bortezomib in Combination with Melphalan and Prednisone (Vmp) in Stem Cell Transplant (Sct) Ineligible Multiple Myeloma (Mm) Patients, presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.